SummitTX Capital’s Avidity Biosciences RNAM Stock Holding History

SummitTX Capital’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-41,091	Closed	-$2.96M	–	941
2025 Q4	$2.96M	Sell	41,091 -8,051	-16%	-$520K	0.09%	239
2025 Q3	$2.14M	Buy	49,142 +27,046	+122%	+$1.09M	0.09%	243
2025 Q2	$628K	Buy	22,096 +3,016	+16%	+$89.9K	0.03%	467
2025 Q1	$563K	Buy	+19,080	New	+$594K	0.02%	517

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

SummitTX Capital's RNAM Position: Q1 2026 in Review

SummitTX Capital sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 41,091 shares — an estimated $2.96M sold.

SummitTX Capital first reported a position in RNAM in Q1 2025 and held it in 4 quarters. The position peaked at $2.96M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

SummitTX Capital reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 41,091 Avidity Biosciences shares in Q1 2026, an estimated $2.96M.
SummitTX Capital first reported a position in Avidity Biosciences in Q1 2025 and held it in 4 quarters.
SummitTX Capital's Avidity Biosciences position peaked at $2.96M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.